QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=3EF2577BC4DBCBF379A24C4BFE185057;jsessionid=09BABAE375E7CDF154CCD35F7CDDAAE4;jsessionid=A67D3BBE7E9D864BAF5F4FB43F51E7CD;jsessionid=FE4423201B008D19958CC58D14642754;jsessionid=7B9F8A4EDDFB7CA3608B46E750D508E3 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=3EF2577BC4DBCBF379A24C4BFE185057;jsessionid=09BABAE375E7CDF154CCD35F7CDDAAE4;jsessionid=A67D3BBE7E9D864BAF5F4FB43F51E7CD;jsessionid=FE4423201B008D19958CC58D14642754;jsessionid=7B9F8A4EDDFB7CA3608B46E750D508E3